Clemson University

TigerPrints
All Theses

Theses

8-2022

ACTIVATION OF THE PPAR NUCLEAR RECEPTORS BY OXYLIPINS
AND THEIR POTENTIAL EFFECTS ON DIFFERENTIATION AND
GENE EXPRESSION IN MYOCYTES
Jazmine Eccles
eccles@g.clemson.edu

Follow this and additional works at: https://tigerprints.clemson.edu/all_theses
Part of the Biology Commons

Recommended Citation
Eccles, Jazmine, "ACTIVATION OF THE PPAR NUCLEAR RECEPTORS BY OXYLIPINS AND THEIR
POTENTIAL EFFECTS ON DIFFERENTIATION AND GENE EXPRESSION IN MYOCYTES" (2022). All Theses.
3821.
https://tigerprints.clemson.edu/all_theses/3821

This Thesis is brought to you for free and open access by the Theses at TigerPrints. It has been accepted for
inclusion in All Theses by an authorized administrator of TigerPrints. For more information, please contact
kokeefe@clemson.edu.

ACTIVATION OF THE PPAR NUCLEAR RECEPTORS BY OXYLIPINS AND
THEIR POTENTIAL EFFECTS ON DIFFERENTIATION AND GENE EXPRESSION
IN MYOCYTES
A Thesis
Presented to
The Graduate School of
Clemson University
In Partial Fulfillment
of the Requirements for the Degree
Master of Science
Biological Sciences
By
Jazmine A. Eccles
August 2022
Accepted by:
Dr. William S. Baldwin, Committee Chair
Dr. Lisa Bain
Dr. Charles Rice

Abstract
Obesity and non-alcoholic fatty liver diseases are a growing issue worldwide. Decreased
expression of CYP2B6 is associated with obesity in humans and Cyp2b-null mice are dietinduced obese; however fatty liver disease is worse in humanized CYP2B6 transgenic mice than
WT or Cyp2b-null mice despite lower obesity. CYP2B6 produces several oxylipins with
preference for metabolism at the 9- and 13-positions with 9-HODE and 13-HODE (from linoleic
acid; n-6), and 9-HOTrE and 13-HOTrE (from a-linolenic acid; n-3) preferentially produced.
Oxylipins serve as signaling molecules for many processes, such as inflammatory pathways,
lipid distribution, and lipid metabolism. Due to their diversity, oxylipins can act as ligands for a
variety of receptors, including the peroxisome proliferator-activated receptors (PPARa/d/g) that
play a role in regulation of lipid metabolism, inflammation, and dyslipidemia. Transactivation
assays for each PPAR revealed the oxylipins 9-HODE and 9-HOTrE are agonists of PPARa, 13HOTrE is an antagonist of PPARd, and 13-oxoODE is an agonist of PPARg. All PPARs play a
role in lipid metabolism, but their expression in tissues varies. Less research has focused on
PPARd, especially as it relates to obesity. PPARd is primarily expressed in skeletal muscle
tissue; therefore, negatively perturbing PPARd activity in skeletal muscle may reduce fat use in
muscle and increase accumulation in other tissues by increasing availability, which can impact
obesity and fatty liver. To determine the effects of 13-HOTrE on skeletal muscle, C2C12
myocytes were exposed to 0.6 to 6 mM 13-HOTrE during differentiation and RNA was extracted
to evaluate gene expression by qPCR.
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Significant changes in several genes related to metabolism, including the sterol
regulatory-element binding proteins (SREBPs) that are required for cholesterol and fatty
acid biosynthesis were observed. In addition, C2C12 myocytes were exposed to 0.6 to 6
mM 13-HOTrE and a Mito-Stress test was performed (SeaHorse, Agilent). 13-HOTrE
increased ATP-coupled mitochondrial metabolism in a concentration-dependent manner.
These results suggests that 13-HOTrE plays a role in inducing pathways related to fatty
acid metabolism and mitochondrial respiration.
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BACKGROUND
Obesity: Obesity is a growing issue worldwide. According to the World Health
Organization (WHO), about 13% of the world’s population was considered obese as of
2016, which is nearly triple the rate reported in 1975 (Hales et.al., 2020). In the United
States, 42.2% of the population was classified as obese as of 2018 (Hales et.al., 2020).
Obesity increases risk factors for several diseases, including type 2 diabetes, nonalcoholic fatty liver diseases (NAFLD), heart diseases, dyslipidemia, and musculoskeletal
disorders (Rossner, 2002). The high rate of disease associated with obesity make it
important to understand the specific mechanism by which it occurs.

Many factors can contribute to obesity, including environmental influences and genetics.
While certain diseases and genetic factors can lead to obesity, the primary cause of
obesity is consumption of excess calories over the rate at which calories are burned
(Spruiell et.al., 2014). This overconsumption of calories leads to storage of excess
calories as fat, which can be stored in adipose tissue or organs such as the liver. A high
fat diet, sometimes referred to as a “westernized diet” due to its prevalence in the US and
other western countries, is the main contributing factor of overconsumption leading to
obesity (Statovci et.al., 2017). While high levels of fat in a western diet can directly
contribute to obesity, increasing evidence suggests types of fats and ratios of these fats
being consumed can also have an influence on obesity and associated diseases (Naughton
et.al., 2016) as does daily activity (Church & Martin 2017), and environmental chemicals
that alter fat distribution called obesogens (Grun & Bloomburg, 2006).
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Non-alcoholic fatty liver disease (NAFLD) is a fatty liver disease associated with obesity.
Due to the rising rate of obesity, the prevalence of NAFLD is also on the rise, with an
estimated 25% of the United States population having fatty liver in some capacity (Wang
et.al., 2021). It is characterized by the accumulation of excessive fats (5% fat by weight)
within the liver, called steatosis, with little to no alcohol consumption (Hashimoto et.at.,
2013). NAFLD is associated with metabolic disease, but fatty liver itself is benign and
reversible, able to be treated by altering diet and exercise habits (Hashimoto et.at., 2013).
Because NAFLD usually does not present with clinical symptoms other than obesity and
metabolic diseases, it is not often diagnosed, and if untreated, can progress to nonalcoholic steatohepatitis (NASH) (Hashimoto et.al., 2013). NASH is characterized by
steatosis progressing to the point of liver injury, which can include inflammation,
hepatocyte ballooning, and fibrosis, which is the development of fibrous connective
tissues (scarring) in response to injury in an effort to repair the liver (Aydın & Akçalı,
2018). Once fibrosis in the liver occurs, this damage may lead to cirrhosis, which in
irreversible (Hashimoto et.al., 2013). Because NAFLD and NASH are associated with
obesity, and obesity has increased worldwide, it has become increasingly important to
understand what leads to this accumulation of fats in the liver and possible treatment
methods.

Poly-unsaturated fatty acids: Poly-unsaturated fatty acids (PUFAs) are fatty acids that
contain more than one double bond in their carbon chain (Ander et.al., 2003). There are
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three classes major classes of PUFAs; n-9, n-6, and n-3 (also called omega-9, omega-6,
and omega-3 fatty acids) with two of these classes being the most biologically relevant,
n-6 and n-3 fatty acids (Murff & Edwards, 2014). They are given their name based on
where the first double bond occurs in the carbon chain, either at the sixth or third carbon
from the methyl end of the chain (Murff & Edwards, 2014). Some of these PUFAs can
only be consumed through diet, being termed as essential fatty acids (EFAs), and these
include the n-6 linoleic acid (LA) and the n-3 alpha-linolenic acid (ALA) (Ander et.al.,
2003). LA and ALA are synthesized within plant tissues, and therefore plants, and more
specifically plant oils, are rich in PUFA content (Calder & Grimble, 2002). Once
consumed, EFAs can be converted to longer chain fatty acids through a series of
enzymatic reactions, resulting in arachidonic acid (AA) from LA and docosahexaenoic
acid (DHA) and eicosapentanoic acid (EPA) from ALA (Murff & Edwards 2014). While
the conversion of EFAs to other fatty acids does occur, it is limited and does not provide
an efficient source of these PUFAs (Abedi & Sahari 2014). Therefore, it is common to
consume AA, DHA, and EPA through the diet as well, primarily through meat and fatty
fish (Friesen & Innes 2010).

PUFAs can be metabolized through enzymatic or non-enzymatic reactions (Gabbs et.al.,
2015). PUFA metabolites created through non-enzymatic reactions include things like
neuroprostanes and isoprostanes, and metabolites created through enzymatic reactions
include eicosanoids, prostanoids, docosanoids, and a variety of other metabolites which
can result from metabolism by lipoxygenases (LOX), cyclooxygenases (COX), and
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cytochrome P450 enzymes (CYPs) (Christie & Hardwood, 2020). PUFA metabolism that
occurs through CYPs can include oxygenation reactions and these oxidized PUFA
metabolites are called oxylipins (Gabbs et.al., 2015).

Figure 1. PUFA metabolism pathways. PUFAs can be metabolized through non-enzymatic reaction to neuroprostanes
and isoprostanes, or through the COX, LOX, or CYP pathways to a variety of metabolites.

Oxylipins are biologically active and found within the body throughout development and
into adulthood (Barquissau et.al., 2017). They are characterized by the PUFA from which
they are derived and show structural and functional diversity due to the variety of PUFAs
that act as precursors for their synthesis (Barquissau et.al., 2017). The structural
differences oxylipins exhibit include length and double bond configuration, which are
determined based on the PUFA from which they are derived, as well as the site of
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oxidation (Barquissau et.al., 2017). This structural diversity leads to functional diversity,
with oxylipins serving as ligands for a wide variety of enzymes and receptors (Barquissau
et.al., 2017). They can act as signaling molecules for a variety of nuclear receptors or Gprotein coupled receptors (GPCR) (Mosblech et.al., 2009), and in some cases, one
oxylipin can act as a ligand for multiple receptors, for example prostaglandin A1, which
can activate all three members of the peroxisome-proliferator activated receptor (PPAR)
nuclear receptor subfamily (Barquissau et.al., 2017). One important group of oxylipins
that shows high levels of biological activity are the oxidized linoleic acid metabolites
(OXLAMs) due to the abundance of LA in the human diet that results in a high
concentration of these specific oxylipins (Vangaveti et.al., 2018). These include 9- and
13-hydroxy-octadecadienoic acid (9- and 13-HODE) and 9- and 13-oxo-octadecadienoic
acid (9- and 13-oxoODE), all of which have been implicated in an assortment of
pathological conditions including cardiovascular diseases and non-alcoholic
steatohepatitis (NASH) (Ramsden et.al., 2012). 13-HODE has been demonstrated as a
ligand for a member of the PPAR family, acting as an agonist of PPARg, while 9-HODE
has been shown to be a ligand for the GPCR GPR132 which may be involved in sensing
and responding to oxidative stress (Vangaveti et.al., 2018).
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13-HODE
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Figure 2. Chemical structure of 9-HODE and 13-HODE and their precursors 9-oxoODE and 13-oxoODE. (Cayman
chemical).

Cytochrome P450 enzymes: Cytochrome P450 enzymes (CYPs) are a superfamily of
enzymes that are responsible for the metabolism of many xenobiotic and endobiotic
chemicals, including conversion of PUFAs to oxylipins (Konkel & Schunck, 2011).
These enzymes play an important role in the metabolism of these chemicals by carrying
out Phase I metabolism (Tomankova et.al., 2017). Phase 1 metabolism involves the
oxidation, reduction, or hydrolysis of chemicals to create a more polar molecule, and this
can result in active metabolites (Allegaert & Anker, 2019). These phase I enzymes can
carry out many detoxification reactions including oxidation reactions, and the oxidation
of PUFAs by these CYPs results in the formation of oxylipins (Tomankova et.al., 2017).
CYPs can be found in all tissues throughout the human body, but the liver is the primary
location of CYP expression (Konkel & Schunck, 2011), especially the detoxification
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CYPs (Kretschmer & Baldwin, 2005). Hepatic CYPs are responsible for the metabolism
of a vast range of xenobiotics, including over half the currently available pharmaceuticals
as well as many environmental chemicals (Tomankova et.al., 2017). Dietary PUFAs are
taken up into the liver after consumption, and here may act as substrates for CYP
enzymes (Lemaire et.al., 2004).

There are 57 functional human CYP genes belonging to 18 different families (Zanger &
Schwab, 2013). They are arranged into families and subfamilies based on their amino
acid sequences, with genes that share 40 percent or more identity assigned to the same
family, which is indicated by a number (ie. CYP2),, and those that share 55 percent or
more identity assigned to the same subfamily, indicated by a letter following the family
number (ie. CYP2B) (Nebert et.al., 2013). The majority of CYPs belong to families 1, 2,
3, and 4 (Zanger & Schwab, 2013). These four families are responsible for the
detoxification metabolism that occurs in the liver, including the metabolism of
eicosanoids, drugs, fatty acids, steroids, bile acids, and other chemicals (Nebert et.al.,
2013).

CYP2B is one of the CYP families primarily expressed in the liver. The murine Cyp2b
family is made up of five members, including 2b9, 2b10, 2b13, 2b19, and 2b23, with the
first three highly expressed mouse liver (Kumar et.al., 2017). In turn, they are the Cyp2b
members that carry out most of the Cyp2b-mediated detoxification and metabolism of
xenobiotics (Kumar et.al., 2017). The other murine Cyp2b members are expressed in skin
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(Cyp2b19) and involved in PUFA metabolism crucial for skin development (Du et.al.,
2005) or expressed in the livers of newborn mice (Cyp2b23) (Peng et.al., 2012). While
mice have five Cyp2b members, CYP2B6 is the only human CYP2B family member, and
this single enzyme has been shown to make up between 2 and 10% of all hepatic CYP
content (Wang & Tompkins, 2008). The CYP2B members in both mice and humans are
transcriptionally regulated by the nuclear receptor constitutive androstane receptor (CAR)
and the transcription factor forkhead box A2 (FoxA2) (Moore et.al., 2000; Hashita et.al.,
2008).

CAR is a member of the orphan nuclear receptor subfamily, meaning it shares many
structural features of the nuclear receptor family but is activated by a variety of
xenobiotic chemicals (Kretschmer & Baldwin, 2005). When activated by the binding of a
ligand, cytoplasmic CAR retention proteins release and CAR translocates from the
cytoplasm to the nucleus where it forms a heterodimer with the retinoid X receptor
(RXR) (Yang & Wang, 2014). This CAR/RXR heterodimer is then able to bind the
response elements in the promotor of CYP2B6 which include the xenobiotic response
enhancer module (XREM) (Wang et.al. 2003) and the phenobarbital-response enhancer
module (PBREM) (Yang & Wang, 2014). This binding leads to the recruitment of coactivators that induce the transcription of target genes (Sueyoshi & Negishi, 2001),
including CYP2B6 (Moore et.al. 2000).
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FoxA2, also known as hepatocyte nuclear factor 3b, is a transcription factor involved in
the development of many tissues, including the liver, and in adulthood is responsible for
regulating genes related to glucose and lipid metabolism (Puigserver & Rodgers 2006).
While CAR is primarily responsible for CYP2B regulation, FoxA2 has more recently
been demonstrated to play a role in the regulation of CYP2B6 (Li et.al. 2016).

CYP2B6 is involved in the metabolism of many xenobiotics but has recently been
demonstrated to metabolize several PUFAs, including ALA, LA, AA, and DHA (Heintz
2020). CYP2B6 preferentially metabolizes ALA, resulting in higher quantities of ALAderived oxylipins such as 9- hydroxy10E,12Z,15Z-octadecatrienoic acid (9-HOTrE) and
13-HOTrE, but also metabolizes LA to oxylipins including 9- and 13-HODE (Heintz
2020) which are further metabolized to 9- and 13-oxoODE, and AA to oxylipins
including 11,12- epoxyeicosatrienoic acid (11,12-EET) and 14,15-EET (Heintz 2020).
These oxylipins can potentially act as signaling molecules for a variety of receptors, and
some have been demonstrated as pro-inflammatory such as 9-HODE (Nieman et.at.
2014) or anti-inflammatory such as 14,15-EET (Falck et.al. 2014). Because oxylipins are
potential signaling molecules, it is possible for them to act on nuclear receptors or other
transcription factors that regulate genes related to lipid homeostasis and metabolism.

Cyp2b members in mice have been demonstrated to play a role in obesity. In several
studies on obesity, Cyp2b9 is the most highly induced Cyp (Hoek-van den et.al., 2015;
Leung et.al., 2016). Cyp2b-knockdown mice treated with an intraperitoneal injection of
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corn oil had increased accumulation of lipids in the liver, had higher levels of serum
lipids, and developed age-onset obesity at a higher rate (Damiri and Baldwin, 2018).
When Cyp2b-null mice are fed a high-fat diet, male mice have a significant weight gain
compared to high-fat diet fed wild-type males, suggesting the lack of Cyp2b plays a role
in this weight gain (Heintz et.al., 2019). Along with studies in mice, human CYP2B6
expression was shown to be negatively correlated with body mass index (BMI), as
individuals with higher BMI showed repression of CYP2B6 (Krogstad et.al., 2020).

Peroxisome Proliferator-Activated Receptors: The peroxisome proliferator-activated
receptors (PPARs) are a group of nuclear receptors that belong to the NR1 family (Janani
& Kumari, 2015). Nuclear receptors are ligand-activated transcription factors that contain
a DNA binding domain and a ligand binding domain (Hwang et.al., 2014). They can be
activated by several different types of ligands, such as fatty acid metabolites, oxysterols,
and hormones, and they regulate genes related to a wide range of processes, such as
metabolism and proliferation (Sever & Glass, 2013). There are seven families of nuclear
receptors; the PPARs belong to one of the largest subfamilies called NR1, which also
includes thyroid hormone receptors, vitamin D receptors, and retinoic acid receptors
(Hwang et.al., 2014). The PPARs are responsible for the regulation of genes that
contribute to a variety of biological processes, such as lipid and glucose homeostasis,
inflammatory responses, and fatty acid synthesis, storage, and mobilization (Janani &
Kumari, 2015). The PPARs include PPARa, PPARd, and PPARg.
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Figure 3. Flowchart of potential PPAR activity and perturbed pathways and tissues. Oxylipins
produced in the liver may act on the PPAR nuclear receptors in several tissues, including the liver,
adipose tissue, and skeletal muscle. Lipid accumulation and metabolism can be influenced by the
PPARs, as well as cell differentiation in adipocytes, and therefore these tissues may experience
changes in lipid metabolism when exposed to these oxylipins.

PPARa is highly expressed in brown adipose tissue and the liver, and to a lesser extent in
the kidneys, skeletal muscle tissue, cardiac muscle tissue, and the small and large
intestines (Contreras et.al., 2013). PPARa functions as a lipid sensor, acting within the
liver to respond to influxes of fatty acids by stimulating the transcription of genes that
metabolize those lipids, such as phospholipid transfer protein (PLTP), 3-Hydroxy-3Methylglutaryl-Coenzyme A Synthase 2 (HMGCS2), Carnitine palmitoyltransferase I
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(CPT-I) and carnitine palmitoyltransferase II (CPT-II), along with other genes involved
in lipoprotein metabolism (Contreras et.al., 2013). PPARa increases lipid catabolism and
utilization and is responsible for the activation of fibroblast growth factor 2 (FGF-2) in
the liver, which plays a prominent role in the starvation response (Contreras et.al., 2013).
PPARa has also been shown to play a role in the regulation of several CYPs in primary
human hepatocytes, including CYP3A4, 2B6, 1A1, 2C8, and 7A1 (Thomas et.al. 2013),
as well as several of the CYP4A family members including CYP4A10 and 4A14
(Patsouris et.al., 2006). The CYP4 members are important enzymes due to their role as ωhydroxylases of endogenous fatty acids (Johnson et.al., 2015). Several studies suggest a
prominent role for PPARa. PPARa-null mice have been shown to be protected against
diet-induced insulin resistance, but also showed increase adiposity (Guerre-Millo et.al.,
2001). This suggests PPARa may play a role in lipid uptake and metabolism in
metabolically active tissues due to the increased uptake of lipids into adipocytes when
PPARa is not present. Other research has shown PPARa expression is increased in the
livers of rats fed a high-fat diet (Lee et.al., 2001). This also suggests PPARa is
upregulated in response to greater fatty acid content in the diet and possibly as a response
to steatosis in the liver. In fact, PPARa ligands (fibrates) have been used to treat
metabolic diseases such as dyslipidemias and atherosclerosis due to their antiinflammatory effects, which suggest other PPARa ligands may also serve as effective
treatments against NAFLD (Liu et.al., 2015).
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PPARd, also called PPARb, is expressed in most metabolically active tissue, including
the liver, skeletal muscle tissue, and adipose tissue, with high levels of expression in
skeletal muscle (Reilly & Lee, 2008). This nuclear receptor has been shown to be
important in the activation of an array of metabolic genes that are involved in glucose
homeostasis and fatty acid synthesis, storage, mobilization, and catabolism (Reilly &
Lee, 2008). PPARd plays a role in the absorption of lipids by regulating genes related to
lipid uptake, such as fatty-acid-binding proteins (FABPs) and Fatty acid transport
proteins (FATPs) (Poirier et.al., 2001). Studies in mice have shown that with constitutive
expression of PPARd in adipocytes, mice were leaner and had a reduction in body fat
composition, while mice with lower PPARd expression were prone to obesity, suggesting
that PPARd may be a widespread regulator of body fat burning and may be a potential
target for treating obesity (Wang et.al., 2003). The role of skeletal muscle is key in this
obesity-protective activation of PPARd, as lipids are taken up and utilized by skeletal
muscle tissue, reducing the potential for accumulation of lipids in other tissues (Wang
et.al., 2003). Research has also shown the importance of PPARd in cardiac muscle tissue,
with one study demonstrating that selected deletion of PPARd in cardiomyocytes of mice
leads to dysfunction of fatty acid oxidation (Cheng et.al., 2004). While this study was
limited to cardiac muscle tissue, many genes affected by this selective PPARd deletion
also regulate fatty acid oxidation within skeletal muscle, which would suggest these
affects may also occur if PPARd were to be inhibited in skeletal muscle. The adverse
effects of reducing fatty acid oxidation could contribute to obesity, as one study showed
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increase fatty acid oxidation was protective against diet-induced obesity (Zhang et.al.,
2012).

PPARg is expressed in white adipose tissue, brown adipose tissue, the spleen, and the
large intestines, with the highest expression being within adipocytes (Janani & Kumari,
2015). PPARg plays a role in the regulation of genes that control adipogenesis, energy
balance, and lipid biosynthesis (Janani & Kumari, 2015). Known agonists of this nuclear
receptor have been used as an effective treatment for insulin resistance and
hyperglycemia (Janani & Kumari, 2015). Adipocytes highly express PPARg as a
protective measure for other tissues from lipid overload, which in turn helps other tissues
and organs maintain normal function, but if overactivated, may lead to adverse effects
such as accumulation of lipids in adipocytes leading to obesity (Janani & Kumari, 2015).
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SPECIFIC AIMS:
Aim I. Quantitative evaluation of oxylipin activation of PPAR nuclear receptors.
Because oxylipins have the ability to activate nuclear receptors and G-coupled proteins
(Barquissau et.al. 2017), it is hypothesized that the oxylipins isolated from humanized
CYP2B6-transgenic mice and CYP2B6 supersomes by Dr. Melissa Heintz (Heintz, 2020)
may activate or inhibit the PPARs. Many oxylipins are present in higher concentrations in
hCYP2B6-transgenic mice than Cyp2b-null mice and several of these were previously
shown to be metabolized by recombinant CYP2B6 (Heintz et.al., 2019). These include 9hydroxy-10E,12Z,15Z-octadecatrienoic acid (9-HOTrE), 13-hydroxy-9Z,11E,15Zoctadecatrienoic acid (13-HOTrE), and 13S-hydroperoxy-9Z,11E,15Z-octadecatrienoic
acid (13-HpOTrE), as well as several others. The oxylipins synthesized by CYP2B6 are
of particular interest because previous data generated in the Baldwin lab show that this
cytochrome P450 enzyme has anti-obesity effects (Heintz et.al., 2019). This work has
been corroborated in human epidemiology studies as CYP2B6 is the only major liver
detoxification CYP in which lower levels are associated with obesity (Krogstad et.al.,
2020).

We will use PPAR-transfected cells to determine what oxylipins are active on PPARs;
a, d, g. After determining which oxylipins are agonists or antagonists of the PPARs, this
activity will be further evaluated using concentration-response assays. The purpose of
this work is to determine which CYP2B6-produced oxylipins are active on the PPARs
and which PPARs may be altered. The PPARs are responsible for regulating genes
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related to lipid metabolism, so these changes in activity may contribute to obesity or fatty
liver disease.

Because PPAR activity differs between tissues, the results provided through aim I were
used to determine future treatments for in vitro experiments.

Aim II. Activation of PPARs by oxylipins in myocytes.
After determining PPAR activity by oxylipins in aim I, the oxylipins showing effects on
PPARs were used to carry out in vitro experiments. As mentioned in aim I, the PPARs
are expressed at varying levels in different tissues, making some tissues more susceptible
to changes in PPAR activity and thus having more influence on pathways of interest.

PPARs are expressed in metabolically active tissues and have the ability to alter lipid
metabolism (Janani & Kumari 2015). PPARa and PPARd are both expressed at high
levels in skeletal muscle tissue, with PPARd being the dominant PPAR in skeletal muscle
(Janani & Kumari 2015). PPARg is also expressed in skeletal muscle tissue, but at lower
levels (Janani & Kumari 2015). Skeletal muscle is an important metabolically active
tissue that can take up and utilize fatty acids and reduce lipid storage (Wang et.al. 2003).
When activated, this increase in utilization of fatty acids can lead to a decrease in
accumulation, which can result in a reduction of body fat due to greater metabolic
activity (Wang et.al. 2003). This has been previously demonstrated using constitutive
expression of PPARd in mice (Wang et.al. 2003). Because of their ability to alter lipid
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metabolism in other metabolically active tissues, it is hypothesized that oxylipins that
activate or inhibit PPARd may alter lipid uptake and utilization pathways in developing
myocytes, which in turn may ultimately affect cell growth, differentiation, and
metabolism. Furthermore, CYP2B6 is primarily hepatic (Wang & Tompkins, 2008);
therefore, our research will suggest a mechanism by which hepatic lipid metabolism
potentially altered by endo- and xenobiotics, can change skeletal muscle energy
utilization patterns.

Diet plays a pivotal role in oxylipin production due to changes in PUFA content
consumed through diet, so changes in diet can lead to alterations in CYP2B6 activity and
oxylipin content in the liver. These changes in the liver then influence other tissues and
alter lipid metabolism in those tissues, which may contribute to obesity. The purpose of
this in vitro work was to determine which oxylipins may agonize or antagonize PPARd in
developing skeletal muscle tissue and what effects this may have on genes related to lipid
metabolism as well as effects on mitochondrial metabolism.
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INTRODUCTION:
Obesity is a growing issue in the United States, as 42.2% of adults are obese according to
a 2017-2018 study, increased from 30.5% in 1999-2000 (Hales et.al., 2020). A study
conducted the same year by the National Health and Nutrition Examination Survey
(NHANES) reported approximately 43.0% of men, 41.9% of women, and 19.3% of
children under the age of 19 are obese (Fryar et.al., 2020). Overconsumption is common
in the US, where diets commonly consist of high-fat foods, leading to a rise in the obese
population (Hales et.al., 2020). This is often called the “Western diet”. Ultimately, excess
fat storage is caused by consuming more calories than the body utilizes, resulting in the
storage of excess calories as fat (Rossner, 2002). Obesity can also be caused other factors
including inherited traits and environmental exposures of chemicals that perturb normal
nutrient signaling processes and induce the storage of fat or inhibit its utilization
(Rossner, 2002). These chemicals are often called obesogens (Grun & Bloomburg, 2006).

Polyunsaturated fatty acids (PUFAs) contain multiple double bonds and their metabolism
produces a number of signaling molecules crucial in inflammation, nutrient allocation,
pain, and development (Ander et.al., 2003). One important family of enzymes
responsible for PUFA metabolism are the cytochrome P450 (CYP) enzymes (Konkel &
Schunck, 2011). CYPs are found in multiple tissues where they are involved in endo- and
xenobiotic metabolism, including bile acid, steroid, fatty acid, drug, and pesticide
metabolism (McDonnell & Dang, 2013). The detoxification CYPs are primarily
expressed in the liver, but not exclusively so (Sadler et.al., 2016). There are four families
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of CYPs (1-4) responsible for the majority of metabolism and detoxification that occurs
in the liver (Hernadez et.al., 2009). Recent studies show the CYP2B family, once thought
to be almost exclusively a detoxification CYP, plays an important role in PUFA
metabolism and obesity (Heintz et.al., 2019). There are five murine Cyp2b members;
CYP2B6 is the only human CYP2B member and has been shown to make up between 2
and 10% of all hepatic CYP activity (Wang & Tompkins, 2008). CYP2B6 metabolizes
PUFAs, such as ALA, LA, and AA, to produce oxidized metabolites called oxylipins
(Heintz, 2020). Oxylipins are biologically active and can serve are ligands for a variety of
receptors, including both nuclear receptors and G-coupled protein receptors (GPCRs)
(Barquissau et.al., 2017).

One family of nuclear receptors that oxylipins may act on is the peroxisome proliferatoractivated receptors, or PPARs (Janani & Kumari 2015). The PPARs consist of three
members; a, d, and g, and are responsible for regulating genes related to lipid
metabolism, glucose homeostasis, and inflammatory responses (Janani & Kumari 2015).
PUFA metabolites have previously been demonstrated as ligands for the PPARs, such as
prostaglandins (Moulin et.al., 2006), but not much research exists on the effects of
CYP2B6-produced oxylipins on the PPARs and how they can potentially influence
obesity, lipid metabolism, and energy utilization.

CYP2B6-containing supersomes produced several oxylipins, including 9-HOTrE, 13HOTrE, 9-HODE, 13-HODE, and others, with preferential production of oxylipins in the
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9- and 13-positions (Heintz, 2020). This included both the ALA and LA produced
oxylipins in vitro with a preference for ALA. In addition, humanized CYP2B6-transgenic
mice (hCYP2B6-Tg) produced multiple oxylipins at greater concentrations than Cyp2bnull mice. The most prominent were 14(15)-epoxy-5Z,8Z,11Z-eicosatrienoic acid (EET)
produced from AA, and 9- hydroxy-octadecadienoic acid (9-HODE), 9,10dihydroxyoctadec-12-enoic acid (DiHOME), and 13-keto-9Z,11E-octadecadienoic acid
(13-KODE) produced from LA. In summary, CYP2B6 metabolizes several PUFAs to a
variety of oxylipins with a preference for metabolism of LA, ALA, and AA at or near the
9- and 13-positions (Heintz, 2020).

While the liver is a primary site of oxylipin production and expresses PPARs, other
tissues have high PPAR activity and may be influenced by liver oxylipins, thus altering
lipid uptake and utilization throughout the body. Skeletal muscle expresses high levels of
PPARd, moderate levels of PPARa, and low PPARg activity (Wang et.al., 2003). Given
that skeletal muscle expresses all three PPARs and is highly metabolically active, it may
serve an important role in lipid metabolism and influence obesity, especially if its ability
to absorb or use lipids is perturbed. C2C12 cells are a line of myoblast that can be
induced to differentiate into myotubes in culture and can serve as an important in-vitro
model for skeletal muscle tissue (McMahon et.al., 1994). These myoblasts express the
PPARs and have been previously used to investigate PPARd activity (Fan et.al., 2017).
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To investigate CYP2B6-produced oxylipin activity on the PPAR nuclear receptors,
agonist and antagonist transactivation assays were performed with a variety of ALA, LA,
DHA, and AA oxylipins produced by CYP2B6 (Heintz, 2020), as well as the PUFAs,
ALA and LA. Subsequent concentration-response studies were performed with positives.
Little work has examined the role of oxylipins on skeletal muscle, nor examined the role
of skeletal muscle activity in obesity caused by obesogens. Therefore, we investigated
oxylipin activity on PPARd-containing C2C12 myoblast cells to determine if perturbing
PPARd activity in muscle can influence fat uptake and utilization.

MATERIALS AND METHODS:
Plasmids: All plasmids were purchased from Addgene (Watertown, MA USA). PPRE
X3-TK-luc was a gift from Bruce Spiegelman (Addgene plasmid # 1015 ;
http://n2t.net/addgene:1015 ; RRID:Addgene_1015), pSG5 PPAR alpha was a gift from
Bruce Spiegelman (Addgene plasmid # 22751 ; http://n2t.net/addgene:22751 ;
RRID:Addgene_22751), pAdTrack-PPARdelta was a gift from Bert Vogelstein
(Addgene plasmid # 16529 ; http://n2t.net/addgene:16529 ; RRID:Addgene_16529), and
PCS4 3XFLAG-PPARgamma1 was a gift from Jaewhan Song (Addgene plasmid #
78769 ; http://n2t.net/addgene:78769 ; RRID:Addgene_78769). DNA sequencing was
performed by Psomagen (Rockville, MD USA) to confirm plasmid sequencing and
quality. Plasmids were received in bacteria as an agar stab and cultured in LB broth
(BRAND) media overnight up to 24 hours. Following culture, plasmids were extracted
using the QIAGEN Plasmid Mini Kit (Qiagen, Frederick, MD USA) and stored at -20oC
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until used for transfections. To store bacteria containing plasmids for future use, bacteria
from overnight culture were transferred to 1.5mL microcentrifuge tubes and flash frozen
using a mixture of dry ice and ethanol. Frozen bacteria were stored at -80oC and cultured
as needed.

Table 1. PPAR plasmids
Plasmid name

Addgene Plasmid number

Reference

PPRE X3-TK-luc

1015

Kim et.al., 1998

pSG5 PPAR alpha

22751

Unpublished.

pAdTrack-PPARdelta

16529

He et.al., 1999

PCS4 3XFLAG-PPARgamma1

78769

Kim et.al., 2014

PPAR transactivation assays: To investigate oxylipin activation of PPARs, murine and
human PPARa (NR1C1), PPARd (NR1C2), and PPARg (NR1C3) reporter assay systems
from Indigo BioSciences (State College, PA) or HepG2 cells transiently transfected with
the PPAR of interest and a Luciferase reporter plasmid were used to perform
transactivation assays according to the manufacturer’s directions and as done previously
(Li et.al., 2014). Transfected cells were exposed to the PUFAs LA or ALA or the
oxylipins 9-HOTrE, 13-HOTrE, 13-HpOTrE, or 9-HODE at 6 µM; or 9,10-dihydroxy12Z-octadecenoic acid (9(10)-DiHOME), 9,10-epoxy-12Z-octadecenoic acid (9(10)EpOME), 11,(12)-epoxy-5Z,8Z,14Z-eicosatrienoic acid (11(12)-EET), 12-hydroxy5Z,8Z,10E,14Z-eicosatetraenoic acid (12-HETE), 13-oxoODE, or 14(15)-epoxy-
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5Z,8Z,11Z-eicosatrienoic acid (14(15)-EET) at 0.6 µM for initial agonist assays.
Oxylipins were purchased from Cayman Chemical Co (Ann Arbor, MI USA) and PUFAs
were purchased from Sigma-Aldrich (St. Louis MO). Agonist assays were performed
with a variety of PUFAs and oxylipins including alpha-linolenic acid and its metabolites
9-HOTrE, 13-HOTrE, and 13-HpOTrE, linoleic acid and its metabolites 9-HODE, 9(10)DiHOME, 9(10)-EpOME, and 13-oxoODE, and the arachidonic acid metabolites 11(12)EET, 12-HETE, and 14(15)-EET. PUFA and oxylipin PPAR activity were initially
screened along with the known agonist for each PPAR (n = 2-3) provided with the kit, the
PPARa agonist GW590735, the PPARd agonist GW0472, and the PPARg agonist
rosiglitazone. All activation assays also included a negative control group that contains
only DMSO to act as a no-activation group. During preliminary screenings, a DMSO
group as well as a media only group were included in assays as negative controls to
determine whether DMSO affects activity of the PPAR of interest to account for the
oxylipins’ solvent with no significant activity observed.

Initial inhibition assays to screen for potential antagonists were performed. The known
agonist included in the kit was used at the concentrations used for agonist assays to
activate the PPAR in all treatment groups. Then a single PUFA or oxylipin at the
concentrations used for agonist assays was added for each treatment group. A negative
control group was also included in each assay that contained DMSO only with no
positive control to determine a zero-response compared to positive only and the possible
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antagonists. The purpose of these assays was to determine if some oxylipins may be
acting as PPAR antagonists.

The reporter cell lines from Indigo Biosciences used for this exposure were transfected
with plasmids containing the PPAR nuclear receptor of interest, along with a luciferase
reporter gene. The luciferase gene is under the control of the PPAR response element
(PPRE), which will only allow the luciferase gene to be expressed when the PPAR is
active. After a 24-hour incubation, the luciferase substrate is added and the reaction
produces a luminescent compound that can then be quantified using a luminescence
reader at 5, 10, 15, 30, or 60 minutes when luciferase is present. The purpose of these
assays was to determine if oxylipins synthesized by CYP2B6 act as agonists or
antagonists of the PPARs.

Concentration response assays were performed using the reporter assay systems from
Indigo Biosciences for evaluation of human PPARs, and HepG2 cells for evaluation of
murine PPARs. HepG2 cells were maintained in standard conditions (37oC, 5% CO2) and
fed with DMEM (Corning) containing 1% ITS (Corning), 1% antibiotics (Gibco), and
10% fetal bovine serum (Corning). Cells were transfected using Effectene transfection
reagent (Qiagen, Frederick, MD USA) according to previously published methods
(Baldwin et al., 2009). HepG2 cells were plated at 100,000 cells per well on 12-well
plates and maintained in standard conditions for 24 hours. Cells were then transfected
with 20ng of an expression plasmid containing the PPAR of interest and 100ng of the
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PPRE reporter plasmid per well. Twenty-four hours post-transfection, cells were treated
with oxylipin concentrations ranging from 0.2-6µM for 24 hours at which time luciferase
activity was measured using the Steady-Glo luciferase assay system (Promega, Madison,
WI USA) according to the manufacturer’s protocol.

Cell Culture and differentiation of C2C12 mouse myoblasts: C2C12 mouse myoblasts
were purchased from ATCC (Manassas, VA USA). Cells were maintained in standard
conditions (37oC, 5% CO2) and fed with DMEM (Corning, Corning, NY) containing 1%
ITS (Corning, Corning, NY), 1% antibiotics (Gibco, Grand Island, NY) and 10% fetal
bovine serum (Corning, Corning NY). Once cells reached 60% confluency, they were
passaged using 0.25% trypsin (Gibco, Grand Island, NY) (Steffens et.al., 2011).

To differentiate myoblasts into myotubes, cells were plated on 6-well plates at 5,000 cells
per well. After growing in standard conditions with growth media until cells reached
100% confluency, approximately three to four days, cells were induced to differentiate by
replacing growth media with differentiation media composed of DMEM supplemented
with 1% ITS, 1% antibiotics, and 2% horse serum (Remel, San Diego, CA), along with
the oxylipin 13-HOTrE at 6µM, 2µM, or 0.6µM or the PPARd agonist GW0742 during
the entirety of the differentiation protocol. The differentiation protocol began on day 0
and media was changed every other day with differentiation was complete on day 4.
After differentiation, cells were harvested using Accutase Enzyme Cell Detachment
Medium (Invitrogen, Carlsbad, CA USA) according to the manufacturer’s instructions.
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After harvesting, cells were frozen in TRIzol reagent (Invitrogen, Carlsbad, CA USA) at 80oC prior to RNA extraction.

Quantitative Real-time PCR (qPCR): Total RNA was extracted from cells using
TRIzol reagent (Invitrogen, Carlsbad, CA USA) according to manufacturer’s instructions.
RNA was quantified on a NanoDrop, then stored at -80oC. RNA extracts were used to
synthesize cDNA using M-MLV Reverse Transcriptase (Promega, Madison, WI USA)
according to standard protocols. Briefly, 2µg of RNA was diluted to a final volume of
25µL in DEPC water (Corning, Corning, NY USA) in RNase-free tubes and incubated at
65oC for 5 minutes. Following this incubation period, 25µL of reverse transcriptase
enzyme solution made from 5µL 5X RT Buffer, 1.625µL a mixture of dNTPs, 0.1µL
random primers, 2µL M-MLV reverse transcriptase enzyme, and 16.275µL DEPC water
was added to each tube, the mixture was mixed by gentle flicking, then incubated at 37oC
for 1 hour. cDNA was stored at -20oC. All reagents for cDNA synthesis were purchased
from Promega.

qPCR was performed using primers specific for Gapdh, Srebp1, Srebp2, Pparg, Fasn,
Cox5b, and Cox6b1. Primer sequences (idtDNA, Coralville, Iowa) and annealing
temperatures can be found in Table 2. 1 µL cDNA was mixed with 12.5µL RT2SYBR
Green ROX qPCR Mastermix (Qiagen, Frederick, MD USA), 9.5µL molecular biology
grade water, 1µL forward primer, and 1µL reverse primer, resulting in a final volume of
25µL per well. All plates were heated to 95oC for 1 minute, followed by 50 cycles of
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denaturation at 95oC for 30 seconds, annealing for 30 seconds at temperatures determined
appropriate for each primer set (Table 2), and elongation for 45 seconds at 72oC,
followed by a melt curve starting at 55oC for 5 seconds up to 95oC for 5 minutes.
Efficiency was determined using a standard curve consisting of a mix of samples diluted
from 1:1 to 1:1024 performed in duplicate or triplicate. Samples were diluted 1:10.
Protocols were carried out and fluorescence measured using a Bio-Rad CFX96 RealTime System. Gene expression was normalized to Gapdh as the housekeeping gene, and
changes in gene expression were quantified using the inverted Muller’s equation (Muller
et al., 2002; Roling et al., 2004).

Table 2. Primer sequences for qPCR
Gene

Forward Sequence

Reverse Sequence

Annealing
Temperature
(℃)

Gapdh

5'-CCTTCATTGACCTCAACTA-3'

5'-CTGGAAGATGGTGATGG-3'

50

Srebp1

5'-ACGAAGTGCACACAAAAGCA-3'

5'-GCCAAAAGACAAGGGGCTAC-3'

58

Srebp2

5'-AGTGGCAACAACAGCAGTGG-3'

5'-GCTTTGCACTTGAGGCTGCA -3'

62

Pparg

5'-TGGGTGAAACTCTGGGAGATTC-3'

5'-AATTTCTTGTGAAGTGCTCATAGGC-

60.1

3'
Fasn

5'-ATTGCATCAAGCAAGTGCAG-3’

5’-GAGCCGTCAAACAGGAAGAG-3’

Cox5b

5’-GATGAGGGAGGAGCAGGCTACTGG-3’

5’-CAGCCAAACCAGATGATA-3’

55

Cox6b1

5’-CTACAAAACTGCCCCCTTTG-3’

5’-GATCTTCCCAGGAAATGTGC-3’

60
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54.2

Energy metabolism: Mitochondrial metabolism was evaluated using a Seahorse XF Cell
Mito Stress test kit (Agilent, Santa Clara, CA). C2C12 cells were plated on a 24-well
Seahorse cell culture assay plate at approximately 25,000 cells per well and immediately
treated with 13-HOTrE at 0.6, 2.0, or 6.0 µM. Cells were incubated with treatments for
24 hours and assayed following the incubation period using the Mito Stress kit according
to manufacturer’s instructions.

Statistical Analysis: Statistical analyses were carried out using GraphPad Prism software
7.0 (San Diego, CA). Significance was determined by one-way ANOVA followed by
Fisher's LSD as the posthoc test.
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RESULTS:
Activation of human and murine PPARa: Preliminary agonist and antagonist screening
assays, using assay systems from Indigo Biosciences, of PUFAs and oxylipins
demonstrated that 9-HOTrE, an oxylipin derived from the n-3 PUFA alpha-linolenic acid,
and 9-HODE, an oxylipin derived from the n-6 PUFA linoleic acid, are agonists of
murine (Figure 4) and human PPARa (Figure 5). No human PPARa antagonists were
identified during these assays (Figure 5). Murine PPARa was not screened for
antagonists due to repeated issues with the assay system. Following screenings, 9-HOTrE
and 9-HODE were used to carry out agonist concentration-response assays (Figure 6).
Concentration-response assays were completed using either Indigo BioSciences kits or
the Effectene transfection method with HepG2 cells at concentrations 0.2-6 µM. These
assays demonstrated that concentrations as low as of 6 µM 9-HOTrE and 2 µM 9-HODE
activated PPARa. Previous studies suggest the parent PUFAs have an IC50 of between 220 µM based on binding assays (Kliewer et.al., 1997).
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Relative Light Units (RLU)

Treatment

Relative Light Units (RLU)

Figure 4. Agonist reporter assays for murine PPARa. Data are presented as mean ± SEM. Statistical significance was
determined by one-way ANOVA followed by Fisher's LSD as the posthoc test (n=2)

Treatment
Figure 5. Agonist and antagonist reporter assays for human PPARa. Data are presented as mean ± SEM. Statistical
significance was determined by one-way ANOVA followed by Fisher's LSD as the posthoc test (n=2)
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Relative Light Units (RLU)

9-HODE Concentration

9-HOTrE Concentration

Figure 6. PPARa agonist concentration-response assay using 9-HOTrE or 9-HODE. Data are presented as
mean ± SEM. Statistical significance was determined by one-way ANOVA followed by Fisher's LSD as the posthoc test
(n=3)

Activation of human and murine PPARg: Preliminary agonist and antagonist screening
assays were performed for PPARg using similar methods to PPARa assays. Based on
agonist assays, 13-oxoODE, a derivative of linoleic acid also referred to as 13-KODE,
was identified as an agonist of murine (Figure 7) and human PPARg (Figure 8). Murine
PPARg was also slightly activated by high concentrations of 9-HOTrE and 9-HODE
(Figure 7). Murine PPARg was also activated by 9-HOTre during the inhibition assay
indicating that is worked as an agonist in this mixture to promote increased activity most
likely through concentration-addition. 9-HOTrE and 9-HODE were not activators of
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human PPARg. Instead, these oxylipins acted as weak antagonists of PPARg (Figure 8).
Following initial screening, 13-oxoODE was used to perform an agonist concentrationresponse assay (Figure 9). Concentrations ranged from 0.06-2µM. This assay showed that
13-oxoODE activated PPARg in a concentration-dependent manner with concentrations
of as low as 0.06µM of 13-oxoODE able to achieve significant activation. This is an
extremely low concentration and much lower than the concentration of linoleic or

Relative Light Units (RLU)

linolenic acid needed for activation of PPARg (Krey et.al., 1997).

Treatment

Figure 7. Agonist and antagonist reporter assays for murine PPARg. Data are presented as mean ± SEM. Statistical
significance was determined by one-way ANOVA followed by Fisher's LSD as the posthoc test (n=2)
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Relative Light Units (RLU)

Treatment

Relative Light Units (RLU)

Figure 8. Agonist and antagonist reporter assays for human PPARg. Data are presented as mean ± SEM. Statistical
significance was determined by one-way ANOVA followed by Fisher's LSD as the posthoc test (n=2)

13-oxoODE Concentration

Figure 9. PPARg agonist concentration-response of 13-oxoODE. Data are presented as mean ± SEM. Statistical
significance was determined by one-way ANOVA followed by Fisher's LSD as the posthoc test (n=3)
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Inhibition of human and murine PPARd: Preliminary agonist and antagonist screening
assays were performed for PPARd using the same methods as previous PPARs. No
agonists of PPARd, neither murine (Figure 10) or human (Figure 11), were identified.
Murine PPARd was inhibited by all three derivatives of alpha-linolenic acid screened, 9HOTrE, 13-HOTrE, and 13-HpOTrE (Figure 10). Human PPARd was only inhibited by
13-HOTrE (Figure 11) and not the other ALA-derived oxylipins. Therefore, future
studies will investigate 13-HOTrE’s effects on skeletal muscle energy utilization and

Relative Light Units (RLU)

gene expression.

Treatment

Figure 10. Agonist and antagonist reporter assays for murine PPARd. Data are presented as mean ± SEM. Statistical
significance was determined by one-way ANOVA followed by Fisher's LSD as the posthoc test (n=2)
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Relative Light Units (RLU)

Treatment

Figure 11. Agonist and antagonist reporter assays for human PPARd. Data are presented as mean ± SEM. Statistical
significance was determined by one-way ANOVA followed by Fisher's LSD as the posthoc test (n=2)

qPCR: Based on the transactivation assay demonstrating 13-HOTrE acted as an
antagonist of PPARd, the effects of 13-HOTrE on downstream gene expression changes
in vitro needed to be evaluated. Skeletal muscle shows high expression of PPARd and
was therefore chosen as a model to evaluate 13-HOTrE’s effects on PPARd activity.
qPCR was performed using C2C12 mouse myoblasts differentiated to myotubes while
exposed to 13-HOTrE at concentrations of 0.6, 2, and 6 µM to assess changes in gene
expression of several genes involved in energy use, d fatty acid uptake, and fatty acid and
cholesterol synthesis. The PPARd agonist GW0742 was used as a reference for PPARd
activation. PPARg expression was not significantly altered by treatment with 13-HOTrE
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(Figure 12), which was expected based on transactivation data (Figure 7), since muscle
tissue has very low levels of PPARg (Manickam et.al., 2020) and 13-HOTrE showed no
activity on PPARg in initial screenings. Srebp1, a transcription factor responsible for
regulation of genes associated with lipogenesis (Infantino et al., 2007), showed increased
expression with treatment 13-HOTrE at all treatment concentrations, but not in a
concentration-dependent manner (Figure 12). Srebp2, a transcription factor associated
with genes related to sterol biosynthesis (Infantino et al., 2007), was upregulated by the
treatment of 13-HOTrE in a concentration-dependent manner (at 2 and 6 µM) (Figure
12). Fasn, an enzyme that catalyzes de novo fatty acid synthesis de novo (Smith et.al.,
2003), was significantly upregulated in all treatment groups (Figure 12). PPARd mRNA
expression was not increased by treatment with 13-HOTrE at any concentration (Figure
12). Cytochrome c oxidase (Cox) is the terminal enzyme in mitochondrial electron
transport chain and has been considered as the possible rate-limiting component of
mitochondrial respiration (Kim et.al., 2015). Cox6b1 and Cox5b are two subunits of the
Cox enzyme required for assembly (Cui et.al., 2006). While there was no change in
Cox5b expression, Cox6b1 was decreased significantly at all treatment concentrations of
13-HOTrE (Figure 12). Overall, 13-HOTrE induced genes in volved in fatty acid, lipid,
and sterol biosynthesis, as well as reducing expression of the mitochondrial subunit
Cox6b1. These genes are regulated by a variety of receptors, including the liver X
receptor (LXR) (Dorotea et.al., 2020) and PPARa (Knight et.al., 2005), as well as
nutrient and hormone availability (Radenne et.al., 2008). Increased expression of the
Srebps and Fasn would lead to an increase in fatty acid synthesis and availability and
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potentially provide an alternate energy source for muscle cells, which usually utilize
glucose as their main source of energy.

Seahorse Mito Stress Assay: A Seahorse XF cell mito stress assay was performed on
C2C12 cells exposed to 13-HOTrE at 0.6, 2, and 6 µM to assess potential changes in
mitochondrial metabolism related to perturbations in PPARd caused by 13-HOTrE. ATPcoupled respiration was dramatically increased at 6µM compared to control (Figure 13),
which may indicate C2C12 cells have an increased energetic demand and require more
ATP production to meet this demand. Greater energetic needs may provide a mechanism
by which the lack of Cyp2b causes obesity (Heintz et.al., 2019). Proton leak was
significantly decreased, which suggests cells are better able to maintain their proton
gradient and more efficiently synthesize ATP, as well as reduce reactive oxygen species
formation (Brooks, 2005).
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13-HOTrE Concentration

Figure 12. Changes in gene expression in C2C12 mouse myoblasts after differentiation into myotubes determined by
qPCR. Genes include Pparg, Srebp1, Srebp2, Fasn, Cox5b, and Cox6b1. Data are presented as mean ± SEM. Statistical
significance was determined by one-way ANOVA followed by Fisher's LSD as the posthoc test (n=3-6)
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OCR (pmol/min)

13-HOTrE Concentration

Figure 13. Alterations in mitochondrial metabolism in C2C12 cells exposed to 13-HOTrE. ATP-coupled respiration
showed an increase at 6µM 13-HOTrE. Data are presented as mean ± SEM. Statistical significance was determined by
one-way ANOVA followed by Fisher's LSD as the posthoc test (n=5).
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DISCUSSION:
Several CYP2B6-produced oxylipins activate or block PPAR nuclear receptors (Table 3).
All the oxylipins identified as activators for the PPARs in this study were derived from
the PUFAs LA or ALA, both of which are found in the “Western diet” primarily found in
the US (Statovci et.al., 2017), and their metabolites have been shown in previous studies
to be altered by human CYP2B6 activity (Heintz, 2020). While both PUFAs are found in
a “western diet,” LA is found at about 10X greater levels, and this increase in n-6 fatty
acids has been associated with an increase in obesity (Chaves et.al., 2019). The n-6
PUFAs are also associated with an increase in inflammation, as they exhibit proinflammatory effects such as increased COX-2 and IL-6, vasoconstrictor activity, and
reactive oxygen species formation (Schimtz and Ecker, 2008). n-3 PUFAs, by contrast,
are associated with anti-inflammatory effects, such as vasodilation, inhibition of platelet
aggregation, and the formation of anti-inflammatory lipoxins (Schimtz and Ecker, 2008).
While an increased ratio of n-3/n-6 PUFAs has been associated with improvements in
inflammation associated with obesity and other metabolic diseases (Liu et.al, 2013; Duan
et.al, 2014), simply comparing PUFA ratios may not be sufficient, as PUFA ratios do not
directly reflect oxylipin profiles, and CYP2B6 preferentially metabolizes the n-6 PUFAs
LA and AA in vivo (Heintz 2020), further reducing oxylipins produced from ALA. While
it is often believed n-6 PUFAs lead to pro-inflammatory effects, evidence shows
oxylipins synthesized from LA and AA are also involved in anti-inflammatory pathways.
For example, 13-HODE synthesized from LA and 12-HETE synthesized from AA have
been shown to inhibit secretion of LtB4 from stimulated leukocytes, reducing
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inflammatory response (Camp 1985). This shows oxylipins produced from the same
precursor can have opposing effects on inflammation and further supports that ratios are
too simplistic when comparing dietary PUFA intake.

Previous research has also demonstrated that high-fat diet fed humanized CYP2B6-Tg
mice were protected against diet-induced obesity compared to Cyp2b-null mice, but these
humanized mice had increased liver triglycerides (Heintz, 2020). This suggests oxylipins
produced by CYP2B6 in vivo may serve as signaling molecules that decrease
accumulation of fat in adipose tissue leading to overall lower weight gain but increased
fat transport into the liver leading to an increase in fatty liver. The oxylipins produced in
vivo include the LA derivatives 9-HODE, 13-oxoODE (also known as 13-KODE), 9(10)DiHOME, and 9(10)-EpOME, the ALA derivatives 9-HOTrE, 13-HOTrE, and 13HpOTrE, and the AA derivatives 11(12)-EET 12-HETE, 14,15-EET (Heintz 2020).

The oxylipins 9-HOTrE, 9-HODE, 13-HOTrE, 13-HpOTrE, and 13-oxoODE are
produced by CYP2B6 and act on the PPAR nuclear receptors. This suggests they can
influence changes in energy and lipid metabolism, as the PPARs are responsible for
regulating genes related to lipid metabolism, fatty acid synthesis, and glucose
homeostasis (Janani & Kumari, 2015). Previous studies have shown the PPARs influence
obesity (Abdelmegeed et.al., 2011; Chamorro-García et.al., 2013), but sometimes in a
negative manner. While PPARa has been demonstrated in several studies to be protective
against metabolic disease and show increased expression and activity in response to a
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high-fat diet (Liu et al., 2015; Lee et.al., 2001), PPARg activation promotes adipogenesis
(Janani & Kumari, 2015), which leads to increased deposit of fats in adipose tissue,
contributing to obesity while increasing glucose sensitivity. Several studies have
determined specific PPAR agonists and their effects; however, little to no studies exist on
CYP-derived oxylipins as ligands for the PPARs and their effects. As demonstrated in
this study, several oxylipins produced by CYP2B6 act as activators for these receptors
(Table 3). Based on this data, oxylipins acting as ligands for the PPARs may be altering
lipid metabolism, which could potentially contribute to protection against diet-induced
obesity observed in hCYP2B6-Tg mice (Heintz, 2020). They could also enhance uptake
of fats and play a role in hCYP2B6-Tg mice propensity for fatty liver disease despite
lower white adipose tissue hypertrophy due to effects on liver PPAR-induced lipid uptake
and metabolism.

Interestingly, 9-HOTrE and 9-HODE had different effects on human and murine
PPARg (Figures 7 and 8). While the amino acid sequences between the two species are
highly conserved (Pap et.al., 2016) and the genes regulated by human and murine PPARg
are similar, the ligand binding sites of the ligand binding domain only share a 5%
similarity (Pott et.al., 2012), resulting in differences in ligand binding for the two species.
This offers a possible explanation as to why 9-HOTrE and 9-HODE acted as weak
agonists in the murine cells while acting as weak antagonists in the human cells.

Table 3. Oxylipins and their influence on PPARs.
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Oxylipin
9-HODE

Parent PUFA Human PPAR activity
LA
PPARa agonist
PPARg antagonist

Murine PPAR activity
PPARa agonist
PPARg agonist

9-HOTrE

ALA

PPARa agonist
PPARg antagonist

PPARa agonist
PPARd antagonist
PPARg agonist

13-HOTrE

ALA

PPARd antagonist

PPARd antagonist

13-HpOTrE

ALA

13-oxoODE

LA

PPARd antagonist

PPARg agonist

PPARg agonist

The oxylipin 13-HOTrE produced by CYP2B6 inhibited PPARd transactivation activity.
PPARd is highly expressed in skeletal muscle and might be reducing energy utilization
and fatty acid metabolism in skeletal muscle. However, 13-HOTrE exposed C2C12
murine skeletal muscle cells showed altered gene expression consistent with agonist
activity of the PPARs such as PPARd (Holtst et.al., 2003). 13-HOTrE induced genes
associated with lipid metabolism, including the Srebps and Fasn, both of which have
been associated with changes in PPAR activity (Knight et.al., 2005). The activation of
these genes may perturb lipid biosynthesis and utilization. For example, Srebp1, also
known as Srepf1, is a key regulator of genes controlling lipogenesis and fatty acid
biosynthesis, and activation of this transcription factor can lead to an increase in
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triglyceride synthesis (Strable & Ntambi, 2010), and Srebp2, also known as Srepbf2,
regulates cholesterol biosynthesis (Strable & Ntambi, 2010) and has been indicated to
play a role in obesity by increasing availability of lipids through increased synthesis and
uptake (Bauer et.al. 2011). Fasn is an enzyme required for fatty acid synthesis, and
increased expression in liver and adipose tissue has also been associated with greater
triglycerides, NAFLD, and obesity (Mayas et.al., 2010) especially in the liver. Taken
together, the increase in expression of these genes would cause an increase in fatty acid
catabolism and synthesis in skeletal muscle, potentially increasing lipid availability in
skeletal muscle and increasing aerobic capacity.

13-HOTrE treatment also down-regulated gene expression related to mitochondrial
respiration, including Cox6b1, an important subunit of the cytochrome c oxidase (Cox)
enzyme (Cui et.al., 2006). Increased Cox6b1 has been associated with increased
mitochondrial respiration (Kim et.al., 2015), so it is possible that decreased expression
may have opposing effects. While there was an observed decrease in Cox6b1 gene
expression at all concentrations, Seahorse Mito-Stress tests showed ATP-coupled
respiration was increased with 13-HOTrE treatment at 6 µM, which is in opposition to
previous research related to Cox expression and mitochondrial respiration. This data
suggests the increase in ATP-coupled respiration seen with 13-HOTrE treatment is due to
other factors not related to Cox6b1 gene expression.
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Furthermore, 13-HOTrE increased mitochondrial oxygen consumption, as ATP-coupled
mitochondrial respiration increased with treatment of 13-HOTrE at 6 µM. An increase in
ATP-coupled respiration suggests an increased energetic demand resulting in increased
production, but mitochondrial dysfunction related to PPAR expression in skeletal muscle
is not completely understood. One study showed muscle specific PPARd-knockout mice
show decreased expression of mitochondrial respiration genes (Zorzano et.al., 2010),
suggesting PPARd plays an important role in mitochondrial function. Another study
demonstrated that mice that show targeted expression of an active form of PPARd in
skeletal muscle show increased endurance due to increased type I muscle fibers, or slow
twitch/oxidative muscle fibers, which have a greater number of mitochondria (Wang
et.al., 2004), which indicates involvement of PPARd in mitochondrial function within
muscle. More recent evidence suggests PPARd may be involved in mitochondrial ATPcoupled respiration, particularly during cell differentiation as it relies heavily upon
mitochondrial biogenesis and function (Lima et.al., 2019), and this data suggests 13HOTrE activation of PPARd may in part contribute to the increase in mitochondrial
respiration observed.

Thus, how we respond to our diet corresponds to both what we eat and our enzyme
profiles at the time we eat. Enzyme profiles can be altered by a variety of circumstances,
including diet (Lottenberg et.al., 2012), toxicant exposure (Humphrey et.al., 2019),
activity level (Mann et.al., 2014), and time of day (Sahar & Sassone-Corsi, 2011). These
changes in enzyme activity can heavily influence how we react to food, which further
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impacts lipid metabolism in different tissues. While some tissues, like adipose tissue, are
more likely to accumulate fats and utilize them as an energy source, skeletal muscle is not
a storage site of fats and is less likely to utilize fats for metabolism, as glucose uptake and
utilization is the primary source of energy for muscle cells (Argilés et.al., 2016). Changes
in enzyme activity and physical activity level, as well as availability of fats consumed
and released by other tissues, can shift skeletal muscle from a glycolytic state to prefer
fats as a major energy source (Hargreaves & Spriet, 2020). Increased expression of genes
related to fatty acid synthesis and consumption seen in skeletal muscle cells during
treatment with 13-HOTrE suggests 13-HOTrE acts as a PPARd agonist in skeletal muscle
as the results of gene expression changes from 13-HOTrE exposure is similar to the
PPARd agonist GW0742. This activation of PPARd may be inducing skeletal muscle
cells to enter a lipid-metabolizing state, which could increase aerobic metabolism, reduce
fat accumulation in multiple tissues, and reduce obesity.

In this study, the oxylipins 9-HOTrE, 9-HODE, 13-HOTrE, 13-HpOTrE, and 13oxoODE produced by CYP2B6 were demonstrated to act as ligands of the PPAR nuclear
receptors (Table 3) with 13-HOTrE being the only oxylipin that activated PPARd.
Because there is little data on the role of PPARd activation on obesity or its activation by
oxylipins, we investigated C2C12 skeletal muscle (myoblasts) cell transcription and
activity following exposure as a potential mechanism to increase activity and reduce
obesity (Wang et al., 2003). 13-HOTrE increased expression of genes that regulate lipid
(Srebp1), sterol (Srebp2), and fatty acid (Fasn) biosynthesis, and decreased expression of
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the mitochondrial subunit Cox6b1, all of which were consistent with the known PPARd
agonist GW0742 (Figure 12). 13-HOTrE also increased ATP-coupled respiration, which
according to recent studies may be increased by PPARd activation (Lima et.al., 2019).

CONCLUSION:
This study demonstrated some of the oxylipins produced by CYP2B6 in vivo can act as
ligands for the PPAR nuclear receptors. 9-HODE and 9-HOTrE acted as agonists for
human and murine PPARa and murine PPARg, while they acted as antagonists of human
PPARg (Table 3). 9-HOTrE also acted as an antagonist of murine PPARd (Table 3). 13HOTrE acted as an antagonist for human and murine PPARd, and 13-HpOTrE also acted
as an antagonist for murine PPARd (Table 3). 13-oxoODE acted an agonist of human and
murine PPARg (Table 3).

Following these assays to determine which oxylipins acted as ligands for the PPARs, 13HOTrE was further investigated in C2C12 skeletal muscle cells (myoblasts) to determine
how antagonism of PPARd affects skeletal muscle gene expression. Contrary to initial
screening, 13-HOTrE exposure resulted in gene expression changes more similar to the
PPARd agonist GW0742, suggesting 13-HOTrE acted as an agonist rather than
antagonist in the C2C12 cells. This could be the result of differences in cell type from the
cells used for screening, such as a difference in co-factors, that ultimately affected how
PPARd responded to 13-HOTrE treatment.
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Due to the growing rate of obesity and non-alcoholic fatty liver disease in the US, it is
important to understand the mechanism by which it occurs. One potential mechanism
includes signaling by PUFA metabolites called oxylipins produced by the cytochrome
P450 enzyme CYP2B6. CYP2B6 has recently been demonstrated as an anti-obesity
enzyme, but at the expense of fatty liver (Heintz, 2020). This suggests that while
CYP2B6 is protective against weight gain, the metabolites it produces may be altering
gene expression and ultimately affect lipid metabolism and distribution, as well as energy
metabolism through mitochondria. This study identified several CYP2B6-mediated
oxylipins that act as ligands for the PPARs nuclear receptors. It also demonstrated the
oxylipin 13-HOTrE acts as a potential PPARd ligand, and in skeletal muscle tissue, may
result in an increase in lipid uptake and metabolism that could contribute to the protective
effects of CYP2B6 against obesity.

Further in vitro studies are needed to investigate the effects of CYP2B6-mediated
oxylipins on the PPARs and the effects these perturbations may have. Utilization of
adipocytes and hepatocytes could provide further insight on the effects of PPAR activity
on lipogenesis, metabolism, and fat storage. 9-HODE and 9-HOTrE are of important
interest due to their effects on PPARa and PPARg, as well as 13-oxoODE for its activity
on PPARg. In vivo studies may also provide insight into how oxylipins affect a variety of
tissues and influence fatty liver and obesity, potentially through the PPARs.
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FUTURE WORK:
To continue this study, oxylipin activity will be evaluated in different cell types. HepG2
cells will be utilized to evaluate PPARa activity when exposed to 9-HODE or 9-HOTrE,
and 3T3-L1 cells will be used to evaluate PPARg activity when exposed to 13-oxoODE.

In vivo work will also be completed, using direct treatment with the oxylipins 9-HODE,
9-HOTrE, 13-oxoODE, or 13-HOTrE to determine tissue-specific effects, including
evaluation of white adipose tissue weight, fat accumulation in the liver, serum lipid
evaluation, RNA-sequencing analysis of liver RNA extracts, and qPCR analysis of other
tissues including skeletal muscle.
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